-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet‑derived growth factor receptor signaling.
- Thread starter ginfreely
- Start date
Abstract
Imatinib is a powerful tyrosine kinase inhibitor that specifically targets BCR‑ABL, c‑KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria‑mediated apoptosis of gastric cancer cells by involving endoplasmic reticulum (ER) stress‑associated activation of c‑Jun NH2‑terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time‑ and dose‑dependent manner. Cell cycle analysis revealed that imatinib‑treated AGS cells were arrested in the G2/M phase of the cell cycle. Moreover, imatinib‑treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor C/EBP homologous protein, an ER stress‑associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5‑Fu synergistically inhibited cell growth, compared with treatment with any of these drugs alone. These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress‑associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet‑derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer.
https://www.fox5atlanta.com/news/my...-aungelique-proctor-shares-surgery-update.amp
Scans showed Aungelique had what's known as a gastrointestinal stromal tumor, or GIST, that was at least 13 centimeters, or just over 5 inches in size.
Emory St. Joseph's Dr. Josh Winer, Aungelique's surgeon, says the tumor was in a tricky place, wrapped around the top part of her stomach.
"So, this tumor was adherent to her diaphragm, her liver, her pancreas, spleen," Dr. Winer explains.
Because this would be a complex surgery, Aungelique Proctor's oncologist at Emory's Winship Cancer Institute wanted her to wait on the operation until they could try to shrink the tumor.
Instead of starting chemotherapy, Aungelique began taking a targeted daily treatment, a pill, known as Gleevec.
She has never lost her hair and says she has experienced no serious side effects.
And, the pill, she says, was the breakthrough she needed.
Within a month or two, Aungelique and her husband Max Anderson, were told the tumor was shrinking, quickly.
"We were blown away," she says. 'Max and I were looking at each other like, 'This is unbelievable!'"
Dr. Winer says the Gleevec shrunk the tumor from 13 centimeters to about 7 centimeters, causing it to pull away from the stomach wall.
"If she hadn't responded and hadn't stopped bleeding, we would have had to take out her whole stomach as well as her spleen, part of her pancreas, part of the diaphragm," Winer says. "So, it was extremely important to have that shrink the way it did."
Scans showed Aungelique had what's known as a gastrointestinal stromal tumor, or GIST, that was at least 13 centimeters, or just over 5 inches in size.
Emory St. Joseph's Dr. Josh Winer, Aungelique's surgeon, says the tumor was in a tricky place, wrapped around the top part of her stomach.
"So, this tumor was adherent to her diaphragm, her liver, her pancreas, spleen," Dr. Winer explains.
Because this would be a complex surgery, Aungelique Proctor's oncologist at Emory's Winship Cancer Institute wanted her to wait on the operation until they could try to shrink the tumor.
Instead of starting chemotherapy, Aungelique began taking a targeted daily treatment, a pill, known as Gleevec.
She has never lost her hair and says she has experienced no serious side effects.
And, the pill, she says, was the breakthrough she needed.
Within a month or two, Aungelique and her husband Max Anderson, were told the tumor was shrinking, quickly.
"We were blown away," she says. 'Max and I were looking at each other like, 'This is unbelievable!'"
Dr. Winer says the Gleevec shrunk the tumor from 13 centimeters to about 7 centimeters, causing it to pull away from the stomach wall.
"If she hadn't responded and hadn't stopped bleeding, we would have had to take out her whole stomach as well as her spleen, part of her pancreas, part of the diaphragm," Winer says. "So, it was extremely important to have that shrink the way it did."
As usual Angmoh the best. GIST stomach cancer patients got to thank him too.
Similar threads
